Loading...
XHKG1873
Market cap225mUSD
Jan 09, Last price  
0.82HKD
1D
-1.20%
1Q
-15.46%
IPO
-83.70%
Name

VIVA Biotech Holdings

Chart & Performance

D1W1MN
XHKG:1873 chart
P/E
P/S
0.77
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
11.25%
Rev. gr., 5y
59.31%
Revenues
2.16b
-9.42%
96,492,000148,245,000210,033,000323,057,000696,958,0002,104,083,0002,379,631,0002,155,578,000
Net income
-116m
L-78.03%
24,473,00076,260,00090,550,000265,872,000-386,880,000287,546,000-528,475,000-116,113,000
CFO
383m
-0.69%
21,118,00027,891,00012,110,00046,012,00043,181,00077,830,000386,051,000383,405,000
Dividend
Jun 16, 20210.01 HKD/sh
Earnings
Jun 26, 2025

Profile

Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure determination of protein, and SPR technology. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins. In addition, the company offers contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs) and intermediates; and trades in APIs, intermediates, and formulations, as well as equity for service. Further, it provides research service; laboratory rental services; and project management and bidding services, as well as sells compounds. The company was incorporated in 2008 and is headquartered in Shanghai, China.
IPO date
May 09, 2019
Employees
2,271
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
2,155,578
-9.42%
2,379,631
13.10%
Cost of revenue
1,954,769
2,104,240
Unusual Expense (Income)
NOPBT
200,809
275,391
NOPBT Margin
9.32%
11.57%
Operating Taxes
43,837
45,055
Tax Rate
21.83%
16.36%
NOPAT
156,972
230,336
Net income
(116,113)
-78.03%
(528,475)
-283.79%
Dividends
Dividend yield
Proceeds from repurchase of equity
(10,274)
BB yield
0.48%
Debt
Debt current
952,441
1,916,180
Long-term debt
982,469
909,030
Deferred revenue
73,123
Other long-term liabilities
1,277,046
(165,324)
Net debt
(139,596)
1,100,025
Cash flow
Cash from operating activities
383,405
386,051
CAPEX
(187,678)
(249,328)
Cash from investing activities
439,174
(372,804)
Cash from financing activities
(429,502)
(143,196)
FCF
491,191
7,975
Balance
Cash
1,036,322
678,569
Long term investments
1,038,184
1,046,616
Excess cash
1,966,727
1,606,203
Stockholders' equity
(51,605)
102,415
Invested Capital
6,919,780
6,913,867
ROIC
2.27%
3.37%
ROCE
2.92%
3.87%
EV
Common stock shares outstanding
2,028,679
1,915,437
Price
1.05
-40.00%
1.75
-62.85%
Market cap
2,130,113
-36.45%
3,352,015
-63.89%
EV
1,990,517
4,452,040
EBITDA
412,025
460,845
EV/EBITDA
4.83
9.66
Interest
176,582
184,674
Interest/NOPBT
87.94%
67.06%